Viewing Study NCT02611908

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 10:57 AM
Ignite Modification Date: 2026-02-25 @ 1:54 AM
Study NCT ID: NCT02611908
Status: WITHDRAWN
Last Update Posted: 2019-01-25
First Post: 2015-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Sponsor: Michael Choi
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Lymphocytic Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CLL View
None cancer View
None obinutuzumab View
None ibrutinib View
None SLL View